MX2017013360A - Métodos para tratar el cáncer. - Google Patents

Métodos para tratar el cáncer.

Info

Publication number
MX2017013360A
MX2017013360A MX2017013360A MX2017013360A MX2017013360A MX 2017013360 A MX2017013360 A MX 2017013360A MX 2017013360 A MX2017013360 A MX 2017013360A MX 2017013360 A MX2017013360 A MX 2017013360A MX 2017013360 A MX2017013360 A MX 2017013360A
Authority
MX
Mexico
Prior art keywords
methods
treating cancer
compound
kits
administering
Prior art date
Application number
MX2017013360A
Other languages
English (en)
Spanish (es)
Inventor
J Li Chiang
Li Youzhi
Gao Yuan
Li Wei
J Hitron Matthew
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of MX2017013360A publication Critical patent/MX2017013360A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017013360A 2015-04-17 2016-04-18 Métodos para tratar el cáncer. MX2017013360A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US201662280947P 2016-01-20 2016-01-20
PCT/US2016/028177 WO2016168856A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Publications (1)

Publication Number Publication Date
MX2017013360A true MX2017013360A (es) 2018-08-01

Family

ID=55854799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013360A MX2017013360A (es) 2015-04-17 2016-04-18 Métodos para tratar el cáncer.

Country Status (16)

Country Link
US (1) US20180085341A1 (https=)
EP (1) EP3283069A1 (https=)
JP (1) JP2018511643A (https=)
KR (1) KR20180006918A (https=)
CN (1) CN107666906A (https=)
AU (1) AU2016247319A1 (https=)
BR (1) BR112017022281A2 (https=)
CA (1) CA2983010A1 (https=)
EA (1) EA201792287A1 (https=)
HK (1) HK1250944A1 (https=)
IL (1) IL255022A0 (https=)
MX (1) MX2017013360A (https=)
PH (1) PH12017501879A1 (https=)
SG (2) SG10201900564WA (https=)
TW (1) TW201713327A (https=)
WO (1) WO2016168856A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN111093660A (zh) * 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER
EP3705893A1 (en) * 2019-03-05 2020-09-09 Humanitas Mirasole S.p.A. Methods to assess the risk of being affected by prostate cancer
WO2020197505A1 (en) * 2019-03-27 2020-10-01 Singapore Health Services Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050566B1 (en) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
US20180085341A1 (en) 2018-03-29
CA2983010A1 (en) 2016-10-20
KR20180006918A (ko) 2018-01-19
EP3283069A1 (en) 2018-02-21
PH12017501879A1 (en) 2018-03-05
IL255022A0 (en) 2017-12-31
AU2016247319A1 (en) 2017-11-02
SG11201708504XA (en) 2017-11-29
SG10201900564WA (en) 2019-02-27
WO2016168856A1 (en) 2016-10-20
TW201713327A (zh) 2017-04-16
HK1250944A1 (zh) 2019-01-18
CN107666906A (zh) 2018-02-06
JP2018511643A (ja) 2018-04-26
BR112017022281A2 (pt) 2018-07-10
EA201792287A1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
PH12017501879A1 (en) Methods for treating cancer
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
PH12020550901A1 (en) Macrocyclic compounds for treating disease
EP4302835A3 (en) Methods of treating ovarian cancer
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
MX379270B (es) Composiciones que comprenden cepas bacterianas.
IL253979B (en) Methods, preparations and kits for cancer treatment
HK1258098A1 (zh) 治疗癌症的方法
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2021006326A (es) Inhibidores de pcna.
MX2016009663A (es) Derivados de icariina.
IL268163A (en) Methods, compositions, and kits for treatment of cancer
JOP20200244A1 (ar) مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
TW201613587A (en) Medical treatments based on anamorelin
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
MX388409B (es) Composiciones y metodos para tratar canceres.
PH12017501880A1 (en) Methods for treating cancer
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2015013021A (es) 5-bromo-indirrubinas.
MX390571B (es) Metodos para tratamiento de cancer de ovario.
ZA201808381B (en) Methods and compositions for treating advanced stage non-small cell lung cancer